Jul 12, 2017
ASCO is pleased to welcome the 2017-2018 ASCO Board of Directors and introduce four newly instated leaders, who began their terms at the conclusion of the Annual Business Meeting during the 2017 ASCO Annual Meeting in Chicago.
Bruce E. Johnson, MD, FASCO, is chief clinical research officer and institute physician at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. He is the director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program.
Monica M. Bertagnolli, MD, FASCO, is chief of the Division of Surgical Oncology at Dana-Farber/Brigham and Women’s Cancer Center, a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Immediate Past President
Daniel F. Hayes, MD, FACP, FASCO, is a professor of internal medicine, the Stuart B. Padnos Professor in Breast Cancer, and the clinical director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center.
Craig R. Nichols, MD, FASCO, is the co-director of the Testicular Cancer Multidisciplinary Clinic at Virginia Mason Medical Center in Seattle. He serves as co-primary investigator on the recently funded Northwest National Cancer Institute Community Oncology Research Program. Dr. Nichols is the executive officer of Cancer Control and Prevention Research for the Southwest Oncology Group.
Peter C. Adamson, MD, is chair of the Children’s Oncology Group, president of the Children’s Oncology Group Foundation, and a professor of pediatrics and pharmacology at The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania.
Charles D. Blanke, MD, FACP, FASCO, is a professor of medicine in the Division of Hematology and Medical Oncology at Oregon Health & Science University’s Knight Cancer Institute.
Linda Bosserman, MD, FACP, FASCO, is an assistant clinical professor and staff physician at City of Hope.
Walter J. Curran Jr., MD, FACR, is the executive director of the Winship Cancer Institute of Emory University, the Lawrence W. Davis Professor and Chair of Emory’s Department of Radiation Oncology, and the associate vice president for cancer at the Woodruff Health Sciences Center.
Stephen B. Edge, MD, FACS, FASCO, is the Vice President for Healthcare Outcomes Policy and Professor of Oncology at the Roswell Park Cancer Institute.
Arti Hurria, MD, FASCO, is director of the Cancer and Aging Research Program, co-leader of the Cancer Control and Population Sciences Program, and associate professor of medical oncology and therapeutics research at City of Hope.
Maha Hussain, MD, FACP, FASCO, is the Cis-Maisel Professor of Oncology, and professor of medicine and urology at the University of Michigan Comprehensive Cancer Center (UMCCC). Dr. Hussain has also served as the associate director for clinical research and co-leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the associate chief for clinical research in the Division of Hematology/Oncology at UMCCC.
Reshma Jagsi, MD, DPhil, is professor and deputy chair of the Department of Radiation Oncology at the University of Michigan, where she is residency program director, treats breast cancer, and conducts health services research.
David Khayat, MD, PhD, FASCO, is the head of the Department of Medical Oncology at Pitié-Salpêtrière Hospital, Paris, France.
Michael P. Kosty, MD, FACP, FASCO, is a member of the Scripps Clinical Medical Group, where he has practiced hematology and medical oncology since 1998. Dr. Kosty has served as director of Scripps Green Cancer Center in La Jolla, CA, since 2008, director of Graduate Medical Education at Scripps Clinic/Scripps Green Hospital since 2002, and as director of the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital since 1997.
J. Chris Nunnink, MD, FASCO, is an attending physician in medical oncology at the University of Vermont Medical Center and an associate professor at the Vermont Cancer Center and the College of Medicine at the University of Vermont.
Conquer Cancer Foundation Board of Directors Chair
Thomas G. Roberts Jr., MD, is a managing member of Farallon Capital Management, LLC, and previously served as an attending oncologist at Massachusetts General Hospital, an instructor of medicine at Harvard Medical School, and a visiting scientist at the Massachusetts Institute of Technology.
Eric J. Small, MD, FASCO, is the deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology.
Jaap Verweij, MD, PhD, FASCO, is a medical oncologist and currently dean of the faculty of medicine at Erasmus University and vice-chair of the Board of Directors at Erasmus Medical Center, Rotterdam, Netherlands.
Jedd D. Wolchok, MD, PhD, is chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine and the associate director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.
2017-2018 ASCO Committee Chairs
Incoming ASCO committee members also began their terms during the 2017 Annual Business Meeting. They are led by the following chairs:
Annual Meeting Education
David R. Spigel, MD
Annual Meeting Scientific Program
Ann H. Partridge, MD, FASCO
John Heymach, MD, PhD
Anthony Alberg, PhD
Katherine A. Janeway, MD
Tara O. Henderson, MD, MPH
Conquer Cancer Foundation Grants Selection
Sarat Chandarlapaty, MD, PhD
Paul Celano, MD
Clinical Practice Guidelines
Manish A. Shah, MD
Thomas William LeBlanc, MD, MA, MHS
Robin Zon, MD, FACP, FASCO
Ana Maria Lopez, MD, MPH
Dinesh Pendharkar, MD, PhD
Sharon Spencer, MD
Lisa A. Carey, MD
Julia L. Close, MD
Quality of Care
Inga Tolin Lennes, MD
State Affiliate Council
Melissa S. Dillmon, MD
Special Awards Selection
Daniel F. Hayes, MD, FACP, FASCO
Workforce Advisory Group
Ryan C. Ramaekers, MD